Voglibose Tablets 0.2 / OD Tablets 0.2 Special Drug Use Surveillance "Long-term Use in Patients With Impaired Glucose Tolerance"

Completed

Brief Summary: The purpose of this study is to determine the safety and efficacy of long-term use of Voglibose (Basen) to prevent progression to type 2 diabetes mellitus in participants with impaired glucose tolerance in the routine clinical setting.

Detailed Description: This is a special drug use surveillance on long-term use of Voglibose (Basen) designed to determine the safety and efficacy of long-term use of Voglibose (Basen) to prevent progression to type 2 diabetes mellitus in participants with impaired glucose tolerance in the routine clinical setting.

Particioants will be patients with impaired glucose tolerance. The planned sample size is 1,000.

The usual adult dosage is 0.2 mg of voglibose administered orally three times daily immediately before each meal.

Recruitment & Eligibility

Inclusion Criteria

Participants must meet all of the following criteria ([1] to [3]) to be included in this study:
1. Determined as having IGT (defined as fasting blood glucose < 126 mg/dL and 2-hour post 75-g oral glucose tolerance test [OGTT] blood glucose of 140-199 mg/dL) without improvement despite treatment with diet therapy and exercise therapy for 3-6 months
2. Meets any of the following conditions:
  
  (i) Concurrently has hypertension*1 (ii) Concurrently has dyslipidemia*2 (iii) Is obese (BMI ≥25 kg/m^2) (iv) Has a family history of diabetes mellitus in relatives to the second degree as defined by Japanese law*3
3. Regularly visits the study site and can be observed for 72 weeks
  - 1: Hypertension: Patients with systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg, or patients on oral antihypertensive medication.
  - 2: Dyslipidaemia: Participants with any of the following conditions or participants on oral antidyslipidemic medication
Hyper LDL cholesterolemia (fasting LDL-cholesterol ≥140 mg/dL)
Hypo HDL cholesterolemia (fasting HDL-cholesterol < 40 mg/dL)
Hypertriglyceridemia (fasting triglyceride ≥150 mg/dL) *3: Relatives to the second degree of consanguinity refer to blood relatives who are the subject's "father or mother, grandfather or grandmother, brothers or sisters, children, or grandchildren." Note that these do not include spouse's relatives.

Exclusion Criteria

Participants meeting either of the following criteria ([1] or [2]) will be excluded:
1. Previously diagnosed with diabetes mellitus
2. Has any contraindications to Basen as specified below:
  
  (i) Severe ketosis, diabetic coma or precoma (ii) Severe infection, perioperative state, or serious trauma (iii) History of hypersensitivity to any ingredients of Basen

Arm && Interventions

Group	Intervention	Description
Voglibose 0.2 mg or OD Tablets 0.2 mg	Voglibose	Voglibose 0.2 mg or OD Tablets 0.2 mg will be administered orally three times daily immediately before each meal.

Primary Outcome Measures

Name	Time	Method
Number of Participants Who Experience at Least One Adverse Events	Up to Week 72
Percentage of Participants With Progression to Type 2 Diabetes Mellitus (T2DM) During Treatment Period	Up to Week 72	Percentage of participants who occurred progression of T2DM during treatment period was reported. Diagnostic criteria for progression of T2DM are: (1) "Blood glucose ≥200 mg/dL at any time, morning fasting blood glucose ≥126 mg/dL, or 2-hour post 75-g (Oral Glucose Tolerance Test) blood glucose ≥200 mg/dL. (2) Two or more glucose measurements obtained on different days that meet the above-mentioned criteria, or (3) A single glucose measurement meeting the above-mentioned criteria if the patient meets any of the following conditions: (i) Has typical symptoms of diabetes mellitus (e.g., dry mouth, polydipsia, polyuria, weight loss) (ii) HbA1C ≥6.5% (JDS value) (iii) Obvious diabetic retinopathy.

Secondary Outcome Measures

Name	Time	Method
Percentage of Participants With Normalization of Impaired Glucose Tolerance (IGT) During Treatment Period	Up to Week 72	Percentage of participants who had normalization of Impaired Glucose Tolerance (IGT) during treatment period was reported. IGT normalization was determined by the survey physician based on the results of the 75-g oral glucose tolerance test (OGTT), glucose metabolism markers, and other data.